![](/img/cover-not-exists.png)
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E. Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, William Gooding, Carmen VisusVolume:
61
Language:
english
Pages:
12
DOI:
10.1007/s00262-011-1100-9
Date:
March, 2012
File:
PDF, 529 KB
english, 2012